PI3K/AKT/mTOR signaling pathway dysregulation is frequently identified in patients with RCC (Han et al., 2017), and inhibitors of mTOR, including everolimus and temsirolimus, have proven efficacious in mRCC (Escudier et al., 2014; Ghidini et al., 2017). The gene discussed is MTOR; the disease is renal cell carcinoma.